Search
Paritaprevir
go.drugbank.com/drugs/DB09297ApprovedInvestigationalParitaprevir is also available as a fixed-dose combination product with [DB09296] and [DB00503] as the FDA- and Health Canada-approved product Technivie. … Paritaprevir is a direct acting antiviral medication used as part of combination therapy to treat chronic Hepatitis C, an infectious liver disease caused by infection with Hepatitis C Virus (HCV).
Categories: Cytochrome P-450 Substrates, P-glycoprotein substratesSynonyms: ,12Z,13aR,14aR,16aS)-N-(cyclopropanesulfonyl)-6-[(5-methylpyrazine-2-carbonyl)amino]-5,16-dioxo-2-[(phenanthridin-6-yl)oxy]-1,2,3,6,7,8,9,10,11,13a,14,15,16,16a-tetradecahydrocyclopropa[e]pyrrolo[1,2-a]Sulfadoxine
go.drugbank.com/drugs/DB01299ApprovedInvestigationalWithdrawnA long acting sulfonamide that is used, usually in combination with other drugs, for respiratory, urinary tract, and malarial infections.
Pirtobrutinib
go.drugbank.com/drugs/DB17472ApprovedInvestigationalPirtobrutinib is a small molecule and a highly selective non-covalent inhibitor of Bruton’s tyrosine kinase (BTK). … [A256758,A256773,L44863] However, other mutations may confer resistance to non-covalent BTK inhibitors such as pirtobrutinib.
Categories: P-glycoprotein inhibitors, P-glycoprotein substratesAripiprazole lauroxil
go.drugbank.com/drugs/DB14185ApprovedIt is a prodrug of [aripiprazole], which acts as a partial agonist at the D2 and 5-HT1A receptors, and as an antagonist at the 5-HT2A receptors [A34289]. … On July 2nd, a different formulation of aripiprazole lauroxil marketed as Aristada Initio was FDA-approved for immediate initiation of Aristada at any dose.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP3A SubstratesEnfuvirtide
go.drugbank.com/drugs/DB00109ApprovedInvestigationalEnfuvirtide is a 36 amino acid biomimetic peptide that is structurally similar to the HIV proteins that are responsible for the fusion of the virus to cell membranes and subsequent intracellular uptake
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2E1 SubstratesVoxelotor
go.drugbank.com/drugs/DB14975Approved[T734] Voxelotor was granted accelerated FDA approval on November 25 2019, as it is likely to be a promising treatment for the 100,000 individuals in the U.S. suffering from the disease, in addition … Voxelotor is a novel hemoglobin S polymerization inhibitor for the treatment of sickle cell disease.
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesChikungunya vaccine (live, attenuated)
go.drugbank.com/drugs/DB18701ApprovedInvestigationalInfection with CHIKV causes chikungunya fever, an illness characterized by acute fever and severe, persistent arthralgia. … [L48726] It is approved for use in patients 18 years of age and older who are at high-risk of exposure to chikungunya virus.
Brivaracetam
go.drugbank.com/drugs/DB05541ApprovedInvestigationalBrivaracetam is a racetam derivative of levetiracetam used in the treatment of partial-onset seizures. Brivaracetam binds SV2A with 20 times higher affinity than levetiracetam [A19184].
Categories: Cytochrome P-450 Substrates, Cytochrome P-450 CYP2B6 SubstratesCanis lupus familiaris hair
go.drugbank.com/drugs/DB10867ApprovedDomestic dog hair is used in allergenic testing.
Mixtures: Animal Allergens, AP Dog Hair and Dander Canis spp, Animal Allergens, AP Dog Hair and Dander Canis sppElamipretide
go.drugbank.com/drugs/DB11981ApprovedInvestigational[A274436] Elamipretide is a synthetic tetrapeptide that selectively binds to cardiolipin, a phospholipid in the inner mitochondrial membrane. … Elamipretide is a mitochondrial cardiolipin binder being investigated for diseases involving mitochondrial dysfunction.